bullish
Giant Biogene Placement - Great Track Record but Previous Deal Didn’t Do Well
371 Views16 Apr 2025 11:01
Giant Biogene (2367 HK) aims to raise up to US$250m via a top-up placement. In this note, we talk about the deal dynamics and run the deal through our ECM framework.
What is covered in the Full Insight:
- Introduction
- Deal Terms
- Performance Analysis
- Aequitas Deal Framework
- Concluding Thoughts
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Giant Biogene Placement - Great Track Record but Previous Deal Didn’t Do Well16 Apr 2025
- Xiaomi US$5.3bn Placement - Relatively Small, Strong Momentum but Is Expensive24 Mar 2025
- BYD US$5.2bn Placement - Large Only in Absolute Size, past Deals Have Done Well03 Mar 2025
- Giant Biogene Placement - Has Been Doing Well but Doesn’t Need the Cash16 May 2024
x